Clinical medicine profile
Benzylpenicillin
Beta-lactam antibiotic — penicillin
- Route
- ORAL / PARENTERAL (agent-dependent)
- Schedule
- POM
- ATC
- Not assigned
- PPB status
- registered
This profile needs source confirmation
A traceable source link is not attached to this profile. Confirm prescribing decisions against the current SmPC and Kenya STG/EML.
Safety essentials
The information most likely to change a prescribing or dispensing decision.
Contraindications
- History of serious immediate hypersensitivity (e.g. anaphylaxis, angioedema, urticaria) to any penicillin.
- Caution with prior severe cephalosporin reaction (cross-reactivity risk).
- Avoid in infectious mononucleosis if using aminopenicillins (rash risk).
Precautions
- Sufficient therapy to eliminate streptococcal infections.
- Serious and occasionally fatal immediate hypersensitivity reactions may occur.
- False-positive urinary glucose (if tested for reducing substances).
Dosing matrix
Population and organ-function guidance, shown together for faster comparison.
For most infections, doses of 0.6 to 4.8 g of benzylpenicillin daily in 2 to 4 divided doses by intramuscular or slow intravenous injection or intravenous infusion may be adequate, but higher doses given intravenously, often by infusion, are more usual for severe infections. Mild to moderate susceptible infections [including throat infec- tions, otitis media, pneumonia, cellulitis, neonatal sepsis]. By intramuscular injection or by slow intravenous injection or infusion [intravenous route recommended in neonates and infants] Neonate under 7 days: 25 mg/kg every 12 hours; dose doubled in severe infection. Neonate 728 days: 25 mg/kg every 8 hours; dose doubled in severe infection Child 1 month18 years: 25 mg/kg every 6 hours; increased to 50 mg/kg every 46 hours [max. 2.4 g every 4 hours] in severe infection Endocarditis [combined with another antibacte- rial if necessary] By slow intravenous injection or infusion Child 1 month18 years: 25 mg/kg every 4 hours, increased if necessary to 50 mg/kg [max. 2.4 g] every 4 hours Meningitis, meningococcal disease By slow intravenous injection or infusion Neonate: 75 mg/kg every 8 hours Child 1 month18 years: 50 mg/kg every 46 hours [max. 2.4 g every 4 hours] Proven or suspected neonatal group B strepto- coccus infection By slow intravenous injection or infusion Neonate under 7 days: 50 mg/kg every 12 hours Neonate 728 days: 50 mg/kg every 8 hours
See label paediatric section if present; otherwise use paediatric formulary — do not extrapolate adult doses.
Renal excretion dominant — reduce dose or extend interval in significant renal impairment; risk of accumulation and seizures at high levels.
- CrCl 0–120: Confirm renal dosing in product SmPC / primary label.
Low intrinsic hepatotoxicity; cholestatic hepatitis rare (notably flucloxacillin/co-amoxiclav patterns for related agents).
Use, effects & interactions
Indications
- Streptococcal (including pneumococcal), gonococcal, and meningococcal infections, anthrax, diphtheria, gas-gangrene, leptospirosis, lyme disease.
- Clinical selection for Benzylpenicillin should follow culture results where relevant, Kenya STG/EML recommendations, and the current product SmPC.
- Class context: Beta-lactam antibiotic — penicillin.
- Confirm site-specific dose, duration and monitoring before prescribing.
Adverse effects
- Hypersensitivity reactions including urticaria, fever, joint pains, rashes, angioedema, anaphylaxis, serum sickness-like reaction
- rarely CNS toxicity including convulsions (especially with high doses or in severe renal impairment), interstitial nephritis, haemolytic anaemia, leucopenia, thrombocytopenia and coagulation disorders
- also reported diarrhoea (including antibiotic-associated colitis).
Drug interactions
Open multi-drug checker ↗- Narrow-spectrum penicillin
- verify hypersensitivity history.
- Serious immediate hypersensitivity reactions can occur even with previous tolerance.
- Use only for proven or strongly suspected bacterial infection.
- Adjust dosage/frequency in severe renal impairment and in neonates with incompletely developed renal function.
- 1 mg of penicillin G = 1667 units
Mechanism & disposition
Inhibits synthesis of bacterial cell wall, causing cell death, hence bactericidal.
Read complete mechanism
Inhibits synthesis of bacterial cell wall, causing cell death, hence bactericidal. Penicillins bind penicillin-binding proteins (PBPs) and inhibit the final transpeptidation step of peptidoglycan synthesis, weakening the bacterial cell wall. Osmotic lysis follows; activity is bactericidal against susceptible organisms in the growth phase. Spectrum and beta-lactamase stability vary by agent (narrow natural penicillins vs aminopenicillins vs antipseudomonal/anti-staphylococcal agents).
Within 1 hour (oral); faster IV
4–8 hours typical (agent/formulation dependent)
ORAL / PARENTERAL (agent-dependent)
is predominantly renal (glomerular filtration and tubular secretion). Dose adjustment is often required in severe renal impairment. Probenecid reduces tubular secretion and prolongs levels.
differ by agent and salt/ester. Most penicillins distribute widely into extracellular fluid; CSF penetration is poor unless meninges are inflamed.
Pregnancy, lactation & diet
Penicillins are generally considered compatible in pregnancy when clearly indicated (decades of clinical use). Prefer agents with the best safety record for the indication; confirm current SmPC.
Usually compatible with breastfeeding; small amounts excreted in milk. Monitor infant for diarrhoea, thrush or rash.
Brands & loaded prices
| Brand | Manufacturer | Pack | Observed price |
|---|---|---|---|
| BENZYL BENZOATE | Not recorded | 100ML | KES 34.40Daima Chemist price-list reference ↗ Source date not recorded · verify current price |
| CYDINE | Not recorded | 1 MEGA INJ VIAL 1*S | KES 15.05Daima Chemist price-list reference ↗ Source date not recorded · verify current price |
| CYDINE INJECTION | MEDCURE HEALTHCARE LTD | Powder For Injection | Unavailable |
| GLAPEN | Benzylpenicillin for injection 1mega | Powder For Injection | Unavailable |
| KAREMEGA 1 INJECTION | KAREMAX INDUSTRIAL LTD | Powder For Solution For Injection | Unavailable |
Sources & review state
Decision support only. Confirm patient-specific decisions against the current product SmPC, Kenya STG/EML, and professional judgement.